QIAGEN Launches QIAsymphony Connect for Automated Clinical Nucleic Acid Extraction
New IVD automation platform standardizes nucleic acid extraction across diverse assay workflows with improved productivity, sample traceability and process safety
Builds on more than 3,300 cumulative placements of the established QIAsymphony platform while using the same QIAsymphony kits and consumables
Supports high-growth applications such as liquid biopsy
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the commercial launch of QIAsymphony Connect, an IVD-compliant platform for automated clinical nucleic acid extraction.
